Randomized Double-Blind Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
This research is being done to see if adding a drug called Everolimus to standard hormonal therapy with Fulvestrant will be of benefit in the treatment of breast cancer.
Description
This research is being done to see if adding a drug called Everolimus to standard hormonal therapy with Fulvestrant will be of benefit in the treatment of breast cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
25 Apr 2024.
Study ID: 1307011893
